Inventor

Louis J. Theodore

Inventor
Lynnwood, WA, US

Overview

24→
Patents
1981–2006
Patent span
Human necessities
Primary field (CPC A)

Patents· 24 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes30%
B82YSpecific uses or applications of nanostructures22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations8%
C07DHeterocyclic compounds7%
C07HSugars7%
C07KPeptides7%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests7%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
Y10TTechnical subjects covered by former us classification3%
B01DSeparation1%
PatentTitleYear
7,115,248'Radiolabeled annexins'20067,078,013'Pretargeting methods and compounds'20066,908,903'Cluster clearing agents'20056,709,652'Pretargeting methods and compounds'20046,416,738'Pretargeting methods and compounds'20026,358,490'Three-step pretargeting methods and compounds'20026,287,536'Two-step pretargeting methods using improved bidtin-active agent conjugates'20016,172,045'Cluster clearing agents'20016,075,010'Small molecular weight ligand-hexose containing clearing agents'20006,022,966'Pretargeting methods and compounds'20006,015,897'Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota'20005,985,826'Methods of using hepatic-directed compounds in pretargeting strategies'19995,955,605'Biotinidase resistant biotin-DOTA conjugates'19995,886,143'Hepatic-directed compounds and reagents for preparation thereof'19995,847,121'Production of nitro-benzyl-dota via direct peptide cyclization'19985,630,996'Two-step pretargeting methods using improved biotin-active agent conjugates'19975,608,060'Biotinidase-resistant biotin-DOTA conjugates'19975,578,287'Three-step pretargeting methods using improved biotin-active agent'19965,541,287'Pretargeting methods and compounds'19965,405,966'Trichothecene conjugates'19955,401,880'Chemical prevention or reversal of cataract by phase separation inhibitors'19955,346,670'Phthalocyanine and tetrabenztriazaporphyrin reagents'19945,135,717'Tetrabenztriazaporphyrin reagents and kits containing the same'19924,297,113'Gas filtration apparatus'1981

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1981Patents assigned to THEODORE LOUIS (1)· patent assignee history
1981Based in New Hyde Park, NY, US· patent location history
1992–1994Patents assigned to BRITISH TECH GROUP USA (2)· patent assignee history
1992–1994Based in Seattle, WA, US· patent location history
1995Patents assigned to OCULON CORP (1)· patent assignee history
1995–2006Based in Lynnwood, WA, US· patent location history
1996–2006Patents assigned to NEORX CORP (17)· patent assignee history
2005–2006Patents assigned to ALETHEON PHARMACEUTICALS INC (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
NEORX CORP171996–2006
ALETHEON PHARMACEUTICALS INC22005–2006
BRITISH TECH GROUP USA21992–1994
OCULON CORP11995
THEODORE LOUISself11981
Locations
LocationPatentsSpan
Lynnwood, Washington, US211995–2006
Seattle, Washington, US21992–1994
New Hyde Park, New York, US11981